Pharmacogenetics Research Network

National Institute of General Medical Sciences (NIGMS). "Availability of administrative supplements to the pharmacogenetics research network to address health disparities." Notice NOT-GM-01-004, 3 April, 2001. 

The authors are supported by the Pharmacogenetics of Anticancer Agents Research (PAAR) and the Comprehensive Research on Expressed Alleles in Therapeutic Evaluation (CREATE) groups within the NIH Pharmacogenetics Research Network (GM63340, GM61393). 

Work in the authors laboratories was supported in part by grants from the Swiss National Science Foundation (U.A. Meyer) and by the Pharmacogenetics Research Network Grant (U-01-GM061373) from the National Institute of General Medical Sciences, Bethesda, MD, U.S.A. (D. A. Flockhart). 

International HapMap Consortium (www.hapmap.org) and the Pharmacogenetics Research Network (http //www.nigms.nih. gov/pharmacogenetics/) by the National Institutes of Health), it is quite likely that genotype-guided therapy of patients with RA will happen in the not too distant future. 

PharmGKB. Stanford University. URL http //www. pharmgkb.org/index.jsp. Part of NIH Pharmacogenetics Research Network (PGRN), a central repository for genetic and clinical information about people who have participated in research studies at various medical centers in the PGRN. 

The assistance of Derek Van Booven is greatly appreciated. This work is supported by the NIH Pharmacogenetics Research Network (UOl GM63340) http //pharmacogenetics.wustl.edu. 

Dresser M (2001). The MDRl C3434T polymorphism effects on P-glycoprotein expression/function and clinical significance. AAPS Pharm Sci3 Commentary 3 1-3, http //www.aapspharmsci.org. Giacomini KM et al. (2007). The Pharmacogenetics Research Network from SNP discovery to clinical drug response. Clin Pharmacol Ther 81 328-345. 

Relling MV, Klein TE (2011) CPIC clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89 464-467... 

---